CN109796351B - 一种盐酸屈他维林中间体的制备新方法 - Google Patents
一种盐酸屈他维林中间体的制备新方法 Download PDFInfo
- Publication number
- CN109796351B CN109796351B CN201811598385.0A CN201811598385A CN109796351B CN 109796351 B CN109796351 B CN 109796351B CN 201811598385 A CN201811598385 A CN 201811598385A CN 109796351 B CN109796351 B CN 109796351B
- Authority
- CN
- China
- Prior art keywords
- prepare
- reaction
- diethoxy
- bromobenzene
- follows
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 title claims abstract description 25
- -1 3, 4-diethoxyphenyl acetate Chemical compound 0.000 claims abstract description 55
- HOUKULZGZUNDGI-UHFFFAOYSA-N 4-bromo-1,2-diethoxybenzene Chemical compound CCOC1=CC=C(Br)C=C1OCC HOUKULZGZUNDGI-UHFFFAOYSA-N 0.000 claims abstract description 50
- YOUNXJAJHCCMNK-UHFFFAOYSA-N 2-(3,4-diethoxyphenyl)ethanamine Chemical compound CCOC1=CC=C(CCN)C=C1OCC YOUNXJAJHCCMNK-UHFFFAOYSA-N 0.000 claims abstract description 44
- FIKUHWAANCXBGJ-UHFFFAOYSA-N 2-(3,4-diethoxyphenyl)acetic acid Chemical compound CCOC1=CC=C(CC(O)=O)C=C1OCC FIKUHWAANCXBGJ-UHFFFAOYSA-N 0.000 claims abstract description 34
- KIADQWSSNHTVNK-UHFFFAOYSA-N 2-(3,4-diethoxyphenyl)acetamide Chemical compound CCOC1=CC=C(CC(N)=O)C=C1OCC KIADQWSSNHTVNK-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 18
- AQVKHRQMAUJBBP-UHFFFAOYSA-N 4-Bromocatechol Chemical compound OC1=CC=C(Br)C=C1O AQVKHRQMAUJBBP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000006200 ethylation reaction Methods 0.000 claims abstract description 15
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940008406 diethyl sulfate Drugs 0.000 claims abstract description 13
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims abstract description 13
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 claims abstract description 13
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 claims abstract description 11
- 230000009471 action Effects 0.000 claims abstract description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 7
- 239000012280 lithium aluminium hydride Substances 0.000 claims abstract description 7
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- WUWYVNHCEGEOGK-UHFFFAOYSA-N ethyl 2-(3,4-diethoxyphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(OCC)C(OCC)=C1 WUWYVNHCEGEOGK-UHFFFAOYSA-N 0.000 claims description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 16
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005885 boration reaction Methods 0.000 claims description 8
- 235000011056 potassium acetate Nutrition 0.000 claims description 8
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 8
- 235000011009 potassium phosphates Nutrition 0.000 claims description 8
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 claims description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
- 238000005580 one pot reaction Methods 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 230000006203 ethylation Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 238000005915 ammonolysis reaction Methods 0.000 claims description 3
- 238000006555 catalytic reaction Methods 0.000 claims description 3
- 239000007810 chemical reaction solvent Substances 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 4
- 238000000034 method Methods 0.000 abstract description 14
- OBDKFHFLERWBBI-UHFFFAOYSA-N 2-(3,4-diethoxyphenyl)acetonitrile Chemical compound CCOC1=CC=C(CC#N)C=C1OCC OBDKFHFLERWBBI-UHFFFAOYSA-N 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 5
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 abstract description 4
- 238000005984 hydrogenation reaction Methods 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000010438 heat treatment Methods 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 238000004321 preservation Methods 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 8
- WXWBNUBJVJKZAS-UHFFFAOYSA-N 2-(3,4-diethoxyphenyl)-n-[2-(3,4-diethoxyphenyl)ethyl]acetamide Chemical compound C1=C(OCC)C(OCC)=CC=C1CCNC(=O)CC1=CC=C(OCC)C(OCC)=C1 WXWBNUBJVJKZAS-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- JBFLYOLJRKJYNV-UHFFFAOYSA-N 1-[(3,4-diethoxyphenyl)methylidene]-6,7-diethoxy-3,4-dihydro-2h-isoquinoline;hydron;chloride Chemical compound Cl.C1=C(OCC)C(OCC)=CC=C1C=C1C2=CC(OCC)=C(OCC)C=C2CCN1 JBFLYOLJRKJYNV-UHFFFAOYSA-N 0.000 description 1
- CWUBOATXSCLVPQ-UHFFFAOYSA-N 2-(3,4-diethoxyphenyl)-2-hydroxyacetonitrile Chemical compound CCOC1=CC=C(C(O)C#N)C=C1OCC CWUBOATXSCLVPQ-UHFFFAOYSA-N 0.000 description 1
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000002087 Endarteritis Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 206010046823 Uterine spasm Diseases 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960002065 drotaverine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811598385.0A CN109796351B (zh) | 2018-12-25 | 2018-12-25 | 一种盐酸屈他维林中间体的制备新方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811598385.0A CN109796351B (zh) | 2018-12-25 | 2018-12-25 | 一种盐酸屈他维林中间体的制备新方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109796351A CN109796351A (zh) | 2019-05-24 |
CN109796351B true CN109796351B (zh) | 2021-08-17 |
Family
ID=66557604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811598385.0A Active CN109796351B (zh) | 2018-12-25 | 2018-12-25 | 一种盐酸屈他维林中间体的制备新方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109796351B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111170847B (zh) * | 2019-12-30 | 2022-02-18 | 江苏联环药业股份有限公司 | 一种制备盐酸屈他维林中间体的新方法 |
CN115073372A (zh) * | 2022-07-05 | 2022-09-20 | 江苏联环药业股份有限公司 | 一种盐酸屈他维林降解杂质的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014202528A1 (en) * | 2013-06-20 | 2014-12-24 | Boehringer Ingelheim International Gmbh | Olefin substituted oxindoles having ampk activity |
-
2018
- 2018-12-25 CN CN201811598385.0A patent/CN109796351B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014202528A1 (en) * | 2013-06-20 | 2014-12-24 | Boehringer Ingelheim International Gmbh | Olefin substituted oxindoles having ampk activity |
Non-Patent Citations (1)
Title |
---|
盐酸屈他维林杂质的合成与表征研究;朱丽丹;《沈阳药科大学硕士学位论文》;20150831;第7页路线2-1 * |
Also Published As
Publication number | Publication date |
---|---|
CN109796351A (zh) | 2019-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108689968B (zh) | 两种化合物及其制备方法和在合成布瓦西坦中的用途 | |
CN111205327A (zh) | 一种瑞德西韦的制备方法 | |
CN109796351B (zh) | 一种盐酸屈他维林中间体的制备新方法 | |
JP2011508767A5 (zh) | ||
CN114524856B (zh) | 一种高纯度植物源胆固醇的合成方法 | |
CN112110828A (zh) | 一种贝派地酸的合成方法及其中间体 | |
WO2000062782A1 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
CN101704796B (zh) | 3-吗啉酮制备方法 | |
CN106518944A (zh) | 甲基泼尼松的制备方法 | |
CN103665084A (zh) | 一种制备醋酸阿比特龙的方法 | |
CN100427460C (zh) | 一种l-正缬氨酸的合成方法 | |
CN111170847B (zh) | 一种制备盐酸屈他维林中间体的新方法 | |
CN101245067B (zh) | 一种恩替卡韦的制备方法及其中间体 | |
US6545149B2 (en) | Synthesis and crystallization of piperazine ring-containing compounds | |
CN111018928B (zh) | 一种天麻素半水合物的合成方法及其应用 | |
CN109942397B (zh) | 一种王浆酸的制备方法 | |
CN111484528A (zh) | 一种替诺福韦艾拉酚胺中间体的制备方法 | |
CN115260094B (zh) | 一种新的盐酸去甲乌药碱的合成方法 | |
CN110684000B (zh) | 苯并呋喃衍生物的制备方法 | |
CN109678701A (zh) | 一种维兰特罗中间体的制备方法 | |
CN109704980B (zh) | 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法 | |
CN115894303B (zh) | 一种(3-氨基双环[1.1.1]戊烷-1-基)氨基甲酸叔丁酯及其中间体的制备方法 | |
CN118026877A (zh) | 一种甲氧氯普胺ep杂质f的制备方法 | |
JPH0434967B2 (zh) | ||
US20030135043A1 (en) | Novel synthesis and crystallization of piperazine ring-containing compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: No.9, Jiankang 1st Road, biological health industrial park, Yangzhou City, Jiangsu Province, 225127 Applicant after: JIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd. Address before: 225006 Wenfeng Road, Guangling District, Yangzhou, Jiangsu Province, No. 21 Applicant before: JIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Huang Kun Inventor after: Wang Dongjun Inventor after: Li Wei Inventor after: Wang Daosheng Inventor after: Chu Qingsong Inventor after: Qin Xiongjian Inventor before: Huang Kun Inventor before: Li Wei Inventor before: Wang Dongjun Inventor before: Wang Daosheng Inventor before: Chu Qingsong Inventor before: Qin Xiongjian |